Literature DB >> 19602006

Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.

Alberto Briganti1, Pierre I Karakiewicz, Felix K-H Chun, Nazareno Suardi, Andrea Gallina, Firas Abdollah, Massimo Freschi, Claudio Doglioni, Patrizio Rigatti, Francesco Montorsi.   

Abstract

OBJECTIVES: Several studies have shown that obesity is associated with more aggressive prostate cancer (PCa) variants. We hypothesized that obesity, quantified as body mass index (BMI), is associated with a higher risk of lymph node invasion (LNI) in patients undergoing extended pelvic lymph node dissection (ePLND).
METHODS: Clinical and pathological data were available for 994 consecutive men with PCa treated with radical prostatectomy (RP) and ePLND at a single European tertiary academic centre. Univariable and multivariable logistic regression analyses addressed the rate of LNI. Covariates consisted of pre-treatment prostate specific antigen (PSA), biopsy Gleason sum, clinical stage history of diabetes mellitus as well as BMI coded as either continuous or categorized (<25, 25.0-29.9, 30 kg/m(2) or more) variable. Predictive accuracy was assessed with area under curve estimates.
RESULTS: Overall LNI was diagnosed in 105 patients (10.6%). Mean number of removed lymph nodes was 18.3 (range 7-60). Of all 994 patients, 372 (37.4%) were normal weight, 518 (52.1%) overweight, and 104 (10.5%) were clinically obese. Prevalence of LNI did not significantly differ across different BMI categories (<25, 25.0-29.9 and 30 kg/m(2) or more; 9.9, 10.6 and 12.5%, respectively; P = 0.75). In logistic regression models, neither continuously coded nor categorized BMI was a significant predictor of LNI at univariable or multivariable analyses (all P-values >or=0.1). Moreover, inclusion of BMI with PSA, clinical stage, biopsy Gleason sum and presence of DM did not increase the ability of these variables to predict LNI (82.2% without BMI vs 82.5% and 82.9% with BMI coded as continuous and categorized variable, respectively; all P >or= 0.4).
CONCLUSIONS: In men undergoing RP and ePLND, increased BMI was not associated with increased risk of lymph node metastases. Therefore, routinely considering patient BMI in risk stratification schemes or prognostic LNI models may not be warranted.

Entities:  

Mesh:

Year:  2009        PMID: 19602006     DOI: 10.1111/j.1442-2042.2009.02330.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  5 in total

Review 1.  Contribution of Adipose Tissue to Development of Cancer.

Authors:  Alyssa J Cozzo; Ashley M Fuller; Liza Makowski
Journal:  Compr Physiol       Date:  2017-12-12       Impact factor: 9.090

2.  Influence of obesity on localized prostate cancer patients treated with radical prostatectomy.

Authors:  Yuan-Yuan Qu; Bo Dai; Yun-Yi Kong; Kun Chang; Ding-Wei Ye; Xu-Dong Yao; Shi-Lin Zhang; Hai-Liang Zhang; Wei-Yi Yang
Journal:  Asian J Androl       Date:  2013-09-16       Impact factor: 3.285

3.  Individual- and neighborhood-level education influences the effect of obesity on prostate cancer treatment failure after prostatectomy.

Authors:  Charnita Zeigler-Johnson; Knashawn H Morales; Karen Glanz; Elaine Spangler; Jonathan Mitchell; Timothy R Rebbeck
Journal:  Cancer Causes Control       Date:  2015-07-14       Impact factor: 2.506

4.  The Relationship between Obesity, Prostate Tumor Infiltrating Lymphocytes and Macrophages, and Biochemical Failure.

Authors:  Charnita Zeigler-Johnson; Knashawn H Morales; Priti Lal; Michael Feldman
Journal:  PLoS One       Date:  2016-08-03       Impact factor: 3.240

5.  Diabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer.

Authors:  Malte Krönig; Christian Haverkamp; Antonia Schulte; Laura Heinicke; Kathrin Schaal; Vanessa Drendel; Martin Werner; Ulrich Wetterauer; Wolfgang Schultze-Seemann; Cordula Annette Jilg
Journal:  World J Surg Oncol       Date:  2017-02-21       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.